Skip to content

AEDV Registry of Primary Cutaneous Lymphoma

Spanish Academy of Dermatology and Venereology (AEDV) Registry of Primary Cutaneous Lymphoma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03646422
Enrollment
2000
Registered
2018-08-24
Start date
2016-09-01
Completion date
2025-01-01
Last updated
2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Sezary Syndrome

Brief summary

Registry of patients with Primary Cutaneous Lymphoma seen at participating centers in Spain. The registry will identify patients with this disease and includes information about stage, diagnostic and therapeutic interventions and willingness to participate in further studies.

Detailed description

Registry of patients with Primary Cutaneous Lymphoma seen at participating centers in Spain. The registry will identify patients with this disease and includes information about stage, diagnostic and therapeutic interventions and willingness to participate in further studies. Data is entered in the registry in each of the participating cutaneous lymphoma clinics. These data are updated at least yearly. Participants receive specific training before starting, and there is an online continuous monitoring system.

Interventions

OTHERRegistry of patients (exposure is Cutaneous Lymphoma)

Sponsors

Fundación Academia Española de Dermatología
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All consecutive patients with primary cutaneous lymphoma

Exclusion criteria

* Not willing to participate

Design outcomes

Primary

MeasureTime frameDescription
Maximum TNM stageThrough study completion, an average every 1 yearProportion
Therapeutic groups usedThrough study completion, an average every 1 yearIncluding drugs, phototherapy, radiotherapy and procedures (blood marrow transplant)
MortalityThrough study completion, an average every 1 yearRate

Countries

Spain

Contacts

Primary ContactIgnacio Garcia-Doval, MD, PhD, MScEpid
investigacion@AEDV.ES+34 91 544 62 84

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026